Se crea la Lung Ambition Alliance con el objetivo de duplicar el índice de supervivencia de cinco años en pacientes con cáncer de pulmón para el 2025
July 08, 2019 11:24 ET
|
AstraZeneca
LONDRES, July 08, 2019 (GLOBE NEWSWIRE) -- En el día de hoy, la Asociación Internacional para el Estudio del Cáncer de Pulmón (IASLC), Guardant Health, la Coalición Mundial del Cáncer de Pulmón...
Lung Ambition Alliance launches with goal to double five-year survival in lung cancer by 2025
July 08, 2019 02:00 ET
|
AstraZeneca
LONDON, July 08, 2019 (GLOBE NEWSWIRE) -- Today, the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca...
AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting
April 16, 2018 17:05 ET
|
AstraZeneca
Phase Ib Study 006 long-term follow-up shows clinical activity in PD-L1 ≥25% and <25% groups in 2nd-line non-small cell lung cancer Phase I Study 10 data shows clinical activity with combination...
AstraZeneca Does Not Recommend or Endorse Unsolicited 'Mini-Tender' Offer
March 22, 2004 11:12 ET
|
AstraZeneca
London, UK, March 22, 2004 (PRIMEZONE) --
AstraZeneca Does Not Recommend or Endorse
Unsolicited "Mini-Tender" Offer
AstraZeneca PLC announced today that it has...